GlobeNewswire by notified

SENISCA strengthens Board with the appointment of Dr. David Chiswell, Ph.D, OBE as Chairman


SENISCA strengthens Board with the appointment of Dr. David Chiswell, Ph.D, OBE as Chairman

Highly experienced biotech veteran to support SENISCA’s rapid development of its senotherapeutic platform

Exeter, UK — 14 November 2023: SENISCA SENISCA, a biotechnology company developing RNA based therapeutics to reverse cellular senescence and treat age-related disease, today announces the appointment of Dr. David Chiswell Ph.D, OBE as Chairman of the Board.

Dr. David Chiswell is one of the UK’s most successful biotechnology executives, with extensive experience in the development of early-stage biotechnology companies over 30 years in the industry. He joins the SENISCA Board having co-founded Cambridge Antibody Technology (CAT) in 1990 and served as its Chief Executive Officer (‘CEO’) from 1996 to 2002, taking CAT onto both the London Stock Exchange and Nasdaq. He also served as CEO of Nabriva Therapeutics from 2009 to 2012, following which he was appointed as CEO of Kymab Ltd. from 2015 to 2018. Dr. Chiswell currently serves as Chairman of Epsilogen Ltd. and is a director of Avillion Bond 2 Development 2 GP and the Schiehallion Fund (LSE:MNTN).

Dr. Chiswell has served as the Chairman of the Board of various biotechnology companies including Albireo, Arrow and Sosei. He was also formerly Chairman of the UK BioIndustry Association, with his major contributions to the industry being recognized with the awarding of an OBE by HM the Queen in 2006.

Dr. Sarah Cole, CEO of SENISCA, commented: “We are honoured to welcome Dr. Chiswell to our Board at SENISCA. His deep knowledge and expertise in the biotechnology sector – particularly in early-stage companies, combined with his strategic expertise will be crucial as we continue our evolution towards becoming a clinical stage biotechnology company developing novel senotherapeutics to treat age-related disease. Our ability to attract someone of David’s calibre speaks volumes about the quality of our science and the strong foundational work our team has undertaken.”

Dr. David Chiswell, Chairman of the Board of SENISCA commented: SENISCA is a revolutionary company with the potential to transform the landscape of senotherapeutic treatments. I am thrilled to be joining the Company as Chairman, and I look forward to collaborating with the Board and leadership team as SENISCA progresses into the next stage of its development.”

- Ends -

For more information
Sarah Cole
Chief Executive Officer, SENISCA

For media
ICR Consilium
Chris Welsh, Evi Useh


SENISCA is an award-winning, RNA therapeutics spinout from the University of Exeter. The Company is focused on modulating RNA biology to treat age-related disease. Underpinned by more than 15 years of world-leading research, SENISCA has identified an officially recognized, novel and druggable component of the cellular ageing (senescence) response, which can be specifically targeted in the context of multiple pharmacological and skin health indications.

The Company is developing a portfolio of proprietary senotherapeutics, that target cell senescence for cellular rejuvenation in the treatment of age-related disease. SENISCA’s senotherapeutics specifically target the novel cellular pathway which causes cell rejuvenation and positively impacts markers of disease modification in patient-derived models. In line with the rapid evolution of the company, R & D activities are focused on IND data generation.

SENISCA’s platform technology has broad applicability for multiple age-related diseases including those of the eyes, lungs, joints, and brain. For many such diseases, current treatments are palliative rather than curative, with varying success rates. These diseases represent a high unmet medical need, are amenable to a local route of therapeutic administration and are driven by senescence. Targeting these specific diseases will streamline progress towards the clinic by avoiding potential pitfalls of systemic delivery.

SENISCA’s novel senotherapeutics will be mined and commercialized through partnership or co-development models that will sit alongside internal programmes. If you would like to learn more about SENISCA, please contact Jennie Jepperson, Executive Assistant at SENISCA (

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Change in the Board of Anoto28.2.2024 23:40:00 CET | Press release

Stockholm, 28 February 2024 – Anoto Group AB (publ) (“Anoto” or the “Company”) announces that Hans Haywood (former CEO of Anoto) and Pedro Pinto has requested their own resignation from the board of Anoto with immediate effect. Anoto board will still consist of Dennis Song as the chairman of the board and Injoon Chung, and is therefore not quorum until the EGM scheduled to be held on March 8, 2024 elects new board members. For further information contact: Dennis Song, Chairman of the Board For more information about Anoto, visit or email Anoto Group AB (publ), Reg.No. 556532-3929, Flaggan 1165, 116 74 Stockholm About Anoto Group Anoto is a publicly held Swedish technology company known globally for innovation in the area of information-rich patterns and the optical recognition of those patterns. It is a leader in digital writing and drawing solutions, having historically used its proprietary technology to develop smartpens and related software. These smartpen

Förändringar i Anotos styrelse28.2.2024 23:40:00 CET | Pressemelding

Stockholm, 28 februari 2024 – Anoto Group AB (publ) ("Anoto" eller "Bolaget") meddelar att Hans Haywood (tidigare VD för Anoto) och Pedro Pinto har begärt eget utträde från styrelsen i Anoto med omedelbar verkan. Anotos styrelse kommer fortfarande att bestå av Dennis Song, som styrelsens ordförande, och Injoon Chung, och är därför inte beslutför förrän den extra bolagsstämma som planeras hållas den 8 mars 2024 väljer nya styrelseledamöter. För ytterligare information kontakta: Dennis Song, styrelseordförande för Anoto För mer information om Anoto, please visit eller email Anoto Group AB (publ), Reg.No. 556532-3929, Flaggan 1165, 116 74 Stockholm Om Anoto Group Anoto är ett börsnoterat svenskt teknikföretag, som är känt i hela världen för innovationer rörande informationsrika mönster och optisk igenkänning av dessa mönster. Företaget är ledande när det gäller lösningar för digitalt skrivande och ritande, och har historiskt sett använt sin egenutvecklade teknol

Vow ASA: Full year and second half of 2023 results28.2.2024 23:11:51 CET | Press release

Oslo, 28 February 2024: Vow ASA (OSE: VOW) revenues for the full year 2023 were NOK 918.5 million, a 17 per cent increase from the year before. EBITDA before non-recurring items was negative NOK 23.4 million for the full year. In addition, the company recorded non-recurring items of negative NOK 31.3 million, mainly related to non-cash balance sheet clean-up in contract accruals. This resulted in a negative EBITDA for the year of NOK 54.7 million versus a positive NOK 85.5 million in 2022. “The year 2023 was a year of high activity and revenue. A large number of projects were successfully delivered. Activity in aftersales was increasing. We also secured important new contracts and moved into position for new projects in new industry verticals,” said Henrik Badin, CEO of Vow ASA. At the end of 2023, the order backlog was NOK 1 034 million and another NOK 921 million in options. The backlog and options are providing visibility for revenues and good margins well into 2025/26. “We have als

European Energy A/S: Notice to convene ordinary general meeting28.2.2024 23:08:42 CET | Press release

Company announcement 7/2024 (28.02.2024) The Board of Directors of the Company hereby convenes an ordinary general meeting of the Company, to be held on: Thursday 14 March 2024 at 09:30 CET at the address of the Company, Gyngemose Parkvej 50, 2860 Søborg, Denmark and electronically on Teams Agenda: Election of Chair of the Annual General Meeting.Report on the activities of the Company.Presentation of the annual report with the auditors’ report for approval and discharge of the Board of Directors and the Executive Board.Resolution on the appropriation of profit or treatment of loss according to the approved annual report.Election of members to the Board of Directors.Decision regarding remuneration to the Board of Directors for the financial year 2024. Amendments to the article of association.Election of Auditor(s).AOB. Attachment Notice to convene ordinary general meeting

European Energy A/S: Full-year Financial Report 2023 - Shows resilience and growth in turbulent year28.2.2024 23:00:49 CET | Press release

Company announcement 6/2024 (28.02.2024) European Energy announces its financial report for the full-year 2023. Highlights: Record high EBITDA of EUR 178m represents a 27% increase, achieving our 2023 financial outlook. This result was driven largely by the sale of energy parks and projects, including a revaluation gain from Kassø, partly offset by increasing staff and external expenses due to higher activityRecord Electricity Generation: In 2023, our total renewable energy production reached a record high level of 1,870 GWh or +140% compared to 2022. As power prices in many markets more than halved during 2023, our power sales profit was stable compared to 2022Profitable Power-to-X Projects: Demonstrated through the profitable farm down of the world's largest e-methanol project in Kassø to Mitsui. Another achievement in 2023 was securing over DKK 1bn from Danish green hydrogen price premium tenders, ensuring significant subsidies for the next decade for three new Danish PtX projects.V

HiddenA line styled icon from Orion Icon Library.Eye